BMX and precursor B-cell acute lymphoblastic leukemia: BMX has previously been found to be antigenic through sero-profiling of adult B-ALL [29] and is already used as a target for the small molecule therapy of mature B-cell malignancies [30,31,32] by virtue of its role in the B-cell receptor pathway.